Lipid Drug Carriers for Cancer Therapeutics : An Insight into Lymphatic Targeting, P-gp, CYP3A4 Modulation and Bioavailability Enhancement
© 2020 The Authors..
In the treatment of cancer, chemotherapy plays an important role though the efficacy of anti-cancer drug administered orally is limited, due to their poor solubility in physiological medium, inability to cross biological membrane, high Para-glycoprotein (P-gp) mediated drug efflux, and pre-systemic metabolism. These all factors cumulatively reduce drug exposure at the target site leading to multidrug resistance (MDR). Lipid based carriers systems has been explored to overcome solubility and permeability related issues of anti-cancer drugs. The lipid based formulations have also been reported to circumvent the effect of P-gp and CYP3A4. Further long chain triglycerides (LCT) has shown their ability to access Lymphatic route over Medium Chain Triglycerides, as the former has been extensively used for targeting anti-cancer drugs at proliferating cells through lymphatic route. Therefore this review tries to reflect the usefulness of lipid based drug carriers systems (viz. liposome, solid lipid nanoparticle, nano-lipid carriers, self-emulsifying, lipidic pro-drugs) in targeting lymphatic system and overcoming issues related to solubility and permeability of anti-cancer drugs. Moreover, we have also tried to reflect how critically lipid based carriers are important in maximizing therapeutic safety and efficacy of anti-cancer drugs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Advanced pharmaceutical bulletin - 10(2020), 4 vom: 07. Sept., Seite 524-541 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chaturvedi, Shashank [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CYP3A4 |
|---|
| Anmerkungen: |
Date Revised 22.10.2020 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.34172/apb.2020.064 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316419516 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316419516 | ||
| 003 | DE-627 | ||
| 005 | 20231225161036.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.34172/apb.2020.064 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1054.xml |
| 035 | |a (DE-627)NLM316419516 | ||
| 035 | |a (NLM)33072532 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chaturvedi, Shashank |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lipid Drug Carriers for Cancer Therapeutics |b An Insight into Lymphatic Targeting, P-gp, CYP3A4 Modulation and Bioavailability Enhancement |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 22.10.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2020 The Authors. | ||
| 520 | |a In the treatment of cancer, chemotherapy plays an important role though the efficacy of anti-cancer drug administered orally is limited, due to their poor solubility in physiological medium, inability to cross biological membrane, high Para-glycoprotein (P-gp) mediated drug efflux, and pre-systemic metabolism. These all factors cumulatively reduce drug exposure at the target site leading to multidrug resistance (MDR). Lipid based carriers systems has been explored to overcome solubility and permeability related issues of anti-cancer drugs. The lipid based formulations have also been reported to circumvent the effect of P-gp and CYP3A4. Further long chain triglycerides (LCT) has shown their ability to access Lymphatic route over Medium Chain Triglycerides, as the former has been extensively used for targeting anti-cancer drugs at proliferating cells through lymphatic route. Therefore this review tries to reflect the usefulness of lipid based drug carriers systems (viz. liposome, solid lipid nanoparticle, nano-lipid carriers, self-emulsifying, lipidic pro-drugs) in targeting lymphatic system and overcoming issues related to solubility and permeability of anti-cancer drugs. Moreover, we have also tried to reflect how critically lipid based carriers are important in maximizing therapeutic safety and efficacy of anti-cancer drugs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a CYP3A4 | |
| 650 | 4 | |a Lipid based carriers | |
| 650 | 4 | |a Lymphatic system | |
| 650 | 4 | |a Metastasis | |
| 650 | 4 | |a P-gp | |
| 700 | 1 | |a Verma, Anurag |e verfasserin |4 aut | |
| 700 | 1 | |a Saharan, Vikas Anand |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advanced pharmaceutical bulletin |d 2011 |g 10(2020), 4 vom: 07. Sept., Seite 524-541 |w (DE-627)NLM233419101 |x 2228-5881 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2020 |g number:4 |g day:07 |g month:09 |g pages:524-541 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.34172/apb.2020.064 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2020 |e 4 |b 07 |c 09 |h 524-541 | ||